Marketing authorisation holder:
Incyte Biosciences Distribution B.V.
1105 BP Amsterdam
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their local authority or to Incyte (by e-mail: firstname.lastname@example.org).
Date of Preparation: November 2023
© 2023, Incyte. All rights reserved.
PEMAZYRE, the PEMAZYRE logo and the Incyte logo are registered trademarks of Incyte.
If you would like to request further medical information, please visit: